Evercore Wealth Management LLC maintained its stake in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 168,414 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Evercore Wealth Management LLC owned 0.15% of AVEO Pharmaceuticals worth $374,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of AVEO. Perceptive Advisors LLC raised its stake in shares of AVEO Pharmaceuticals by 64.3% in the 1st quarter. Perceptive Advisors LLC now owns 5,108,808 shares of the biopharmaceutical company’s stock valued at $3,014,000 after purchasing an additional 2,000,000 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of AVEO Pharmaceuticals by 48.6% in the 2nd quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock valued at $7,884,000 after purchasing an additional 1,162,232 shares in the last quarter. EAM Investors LLC acquired a new stake in shares of AVEO Pharmaceuticals in the 2nd quarter valued at about $1,979,000. Sabby Management LLC acquired a new stake in shares of AVEO Pharmaceuticals in the 1st quarter valued at about $513,000. Finally, UBS Oconnor LLC acquired a new stake in shares of AVEO Pharmaceuticals in the 1st quarter valued at about $291,000. Institutional investors and hedge funds own 53.76% of the company’s stock.

Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) opened at 3.53 on Thursday. The company’s 50-day moving average is $3.26 and its 200 day moving average is $1.68. The firm’s market cap is $417.62 million. AVEO Pharmaceuticals, Inc. has a 1-year low of $0.50 and a 1-year high of $4.24.

A number of equities research analysts have recently issued reports on the stock. Piper Jaffray Companies upped their target price on shares of AVEO Pharmaceuticals from $3.80 to $4.50 and gave the company an “overweight” rating in a research note on Monday, August 28th. BidaskClub upgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 16th. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research note on Monday, July 24th. FBR & Co restated an “outperform” rating and issued a $3.00 target price on shares of AVEO Pharmaceuticals in a research note on Thursday, July 13th. Finally, ValuEngine upgraded shares of AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 24th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $3.42.

COPYRIGHT VIOLATION NOTICE: “AVEO Pharmaceuticals, Inc. (AVEO) Position Maintained by Evercore Wealth Management LLC” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/28/aveo-pharmaceuticals-inc-aveo-position-maintained-by-evercore-wealth-management-llc.html.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Want to see what other hedge funds are holding AVEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO).

Institutional Ownership by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Stock Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.